Profile
Peter G.
Linde is currently the Chief Medical Officer at Walden Biosciences, Inc. He previously worked as the Senior Director-Clinical Development at FibroGen, Inc. and as the Vice President-Medical Research at Acceleron Pharma, Inc. From 2020 to 2021, he served as the Chief Medical Officer at Morphic Holding, Inc. Linde received his undergraduate degree from the Massachusetts Institute of Technology.
Peter G. Linde active positions
| Companies | Position | Start |
|---|---|---|
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Provides renal therapeutics services | Corporate Officer/Principal | 10/10/2022 |
Former positions of Peter G. Linde
| Companies | Position | End |
|---|---|---|
| MORC HOLD | Chief Tech/Sci/R&D Officer | 30/12/2021 |
| KYNTRA BIO, INC. | Corporate Officer/Principal | - |
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - |
Training of Peter G. Linde
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company which develops protein therapeutics for cancer and orphan diseases | Health Technology |
FibroGen, Inc.
FibroGen, Inc. Pharmaceuticals: MajorHealth Technology Develops biotechnology-based drugs | Health Technology |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Morphic Holding, Inc.
Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Provides renal therapeutics services | Health Services |
- Stock Market
- Insiders
- Peter G. Linde
















